0	10	Inhibition	Inhibition	NNP
11	13	of	of	IN
14	28	IL-4-inducible	il-4-inducible	JJ
29	33	gene	gene	NN
34	44	expression	expression	NN
45	47	in	in	IN
48	53	human	human	JJ
54	63	monocytes	monocyte	NNS
64	66	by	by	IN
67	71	type	type	NN
72	73	I	i	CD
74	77	and	and	CC
78	82	type	type	NN
83	85	II	ii	CD
86	97	interferons	interferon	NNS
97	98	.	.	.

100	103	The	the	DT
104	112	Th2-type	th2-type	JJ
113	122	cytokines	cytokine	NNS
122	123	,	,	,
124	137	interleukin-4	interleukin-4	NN
138	139	(	(	(
139	143	IL-4	il-4	NN
143	144	)	)	)
145	148	and	and	CC
149	163	interleukin-13	interleukin-13	NN
164	165	(	(	(
165	170	IL-13	il-13	NN
170	171	)	)	)
171	172	,	,	,
173	179	induce	induce	VBP
180	190	expression	expression	NN
191	193	of	of	IN
194	195	a	a	DT
196	204	distinct	distinct	JJ
205	211	subset	subset	NN
212	214	of	of	IN
215	220	genes	gene	NNS
221	223	in	in	IN
224	229	human	human	JJ
230	239	monocytes	monocyte	NNS
239	240	,	,	,
241	250	including	include	VBG
251	264	FcepsilonRIIb	FcepsilonRIIb	NNP
265	266	(	(	(
266	270	CD23	CD23	NNP
270	271	)	)	)
271	272	,	,	,
273	288	15-lipoxygenase	15-lipoxygenase	NNP
288	289	,	,	,
290	294	IL-1	il-1	NN
295	303	receptor	receptor	NN
304	314	antagonist	antagonist	NN
315	316	(	(	(
316	322	IL-1ra	IL-1ra	NNP
322	323	)	)	)
323	324	,	,	,
325	328	and	and	CC
329	333	type	type	NN
334	335	I	i	CD
336	339	and	and	CC
340	344	type	type	NN
345	347	II	ii	CD
348	352	IL-1	IL-1	NNP
353	362	receptors	receptor	NNS
363	364	(	(	(
364	369	IL-1R	IL-1R	NNP
369	370	)	)	)
370	371	.	.	.

372	376	Type	type	NN
377	378	I	i	CD
379	390	interferons	interferon	NNS
391	392	(	(	(
392	401	IFN-alpha	IFN-alpha	NNP
402	405	and	and	CC
406	414	IFN-beta	IFN-beta	NNP
414	415	)	)	)
416	419	and	and	CC
420	424	type	type	NN
425	427	II	ii	CD
428	438	interferon	interferon	NN
439	440	(	(	(
440	449	IFN-gamma	IFN-gamma	NNP
449	450	)	)	)
451	458	inhibit	inhibit	VBP
459	468	induction	induction	NN
469	471	of	of	IN
472	477	these	these	DT
478	483	genes	gene	NNS
484	486	by	by	IN
487	491	IL-4	il-4	NN
492	495	and	and	CC
496	501	IL-13	il-13	NN
501	502	.	.	.

503	510	However	however	RB
510	511	,	,	,
512	515	the	the	DT
516	525	mechanism	mechanism	NN
526	528	by	by	IN
529	534	which	which	WDT
535	539	IFNs	ifn	NNS
540	547	mediate	mediate	VBP
548	552	this	this	DT
553	563	inhibition	inhibition	NN
564	567	has	have	VBZ
568	571	not	not	RB
572	576	been	be	VBN
577	584	defined	define	VBN
584	585	.	.	.

586	588	In	in	IN
589	593	this	this	DT
594	602	overview	overview	NN
602	603	,	,	,
604	606	we	we	PRP
607	614	discuss	discuss	VBP
615	618	the	the	DT
619	623	role	role	NN
624	626	of	of	IN
627	630	the	the	DT
631	644	transcription	transcription	NN
645	651	factor	factor	NN
651	652	,	,	,
653	658	STAT6	STAT6	NNP
659	660	(	(	(
660	666	signal	signal	NN
667	677	transducer	transducer	NN
678	681	and	and	CC
682	691	activator	activator	NN
692	694	of	of	IN
695	710	transcription-6	transcription-6	NN
710	711	)	)	)
712	714	in	in	IN
715	724	mediating	mediate	VBG
725	730	IL-4-	il-4-	NN
731	734	and	and	CC
735	748	IL-13-induced	il-13-induced	JJ
749	753	gene	gene	NN
754	764	expression	expression	NN
765	767	in	in	IN
768	777	monocytes	monocyte	NNS
777	778	.	.	.

779	781	We	we	PRP
782	786	also	also	RB
787	794	discuss	discuss	VBP
795	798	our	our	PRP$
799	805	recent	recent	JJ
806	814	findings	finding	NNS
815	819	that	that	IN
820	824	type	type	NN
825	826	I	i	CD
827	830	and	and	CC
831	835	type	type	NN
836	838	II	ii	CD
839	843	IFNs	IFN	NNP
844	852	suppress	suppress	VBP
853	873	IL-4/IL-13-inducible	il-4/il-13-inducible	JJ
874	878	gene	gene	NN
879	889	expression	expression	NN
890	892	by	by	IN
893	903	inhibiting	inhibit	VBG
904	912	tyrosine	tyrosine	NN
913	928	phosphorylation	phosphorylation	NN
929	932	and	and	CC
933	940	nuclear	nuclear	JJ
941	954	translocation	translocation	NN
955	957	of	of	IN
958	963	STAT6	STAT6	NNP
963	964	.	.	.

965	968	The	the	DT
969	976	ability	ability	NN
977	979	of	of	IN
980	984	type	type	NN
985	986	I	i	CD
987	990	and	and	CC
991	995	type	type	NN
996	998	II	ii	CD
999	1003	IFNs	IFN	NNP
1004	1006	to	to	TO
1007	1014	inhibit	inhibit	VB
1015	1033	IL-4/IL-13-induced	il-4/il-13-induced	JJ
1034	1039	STAT6	STAT6	NNP
1040	1048	activity	activity	NN
1049	1051	is	be	VBZ
1052	1057	dose-	dose-	NN
1058	1061	and	and	CC
1062	1076	time-dependent	time-dependent	JJ
1076	1077	,	,	,
1078	1081	and	and	CC
1082	1084	is	be	VBZ
1085	1088	not	not	RB
1089	1095	unique	unique	JJ
1096	1098	to	to	TO
1099	1108	monocytes	monocyte	NNS
1109	1116	because	because	IN
1117	1121	IFNs	IFN	NNP
1122	1128	induce	induce	VBP
1129	1132	the	the	DT
1133	1137	same	same	JJ
1138	1145	effects	effect	NNS
1146	1148	in	in	IN
1149	1160	fibroblasts	fibroblast	NNS
1160	1161	.	.	.

1162	1172	Inhibition	Inhibition	NNP
1173	1175	of	of	IN
1176	1181	STAT6	STAT6	NNP
1182	1190	activity	activity	NN
1191	1193	is	be	VBZ
1194	1197	not	not	RB
1198	1205	evident	evident	JJ
1206	1212	unless	unless	IN
1213	1218	cells	cell	NNS
1219	1222	are	be	VBP
1223	1235	preincubated	preincubate	VBN
1236	1240	with	with	IN
1241	1244	IFN	IFN	NNP
1245	1248	for	for	IN
1249	1251	at	at	IN
1252	1257	least	least	JJS
1258	1259	1	1	CD
1260	1261	h	h	NN
1262	1268	before	before	IN
1269	1273	IL-4	il-4	NN
1274	1285	stimulation	stimulation	NN
1285	1286	.	.	.

1287	1298	Furthermore	furthermore	RB
1298	1299	,	,	,
1300	1310	inhibition	inhibition	NN
1311	1314	can	can	MD
1315	1317	be	be	VB
1318	1325	blocked	block	VBN
1326	1328	by	by	IN
1329	1340	actinomycin	actinomycin	NN
1341	1342	D	D	NNP
1342	1343	,	,	,
1344	1354	indicating	indicate	VBG
1355	1356	a	a	DT
1357	1368	requirement	requirement	NN
1369	1372	for	for	IN
1373	1375	de	de	FW
1376	1380	novo	novo	FW
1381	1394	transcription	transcription	NN
1394	1395	.	.	.

1396	1398	We	we	PRP
1399	1406	propose	propose	VBP
1407	1408	a	a	DT
1409	1414	model	model	NN
1415	1417	in	in	IN
1418	1423	which	which	WDT
1424	1435	stimulation	stimulation	NN
1436	1438	of	of	IN
1439	1448	monocytes	monocyte	NNS
1449	1451	by	by	IN
1452	1455	IFN	IFN	NNP
1456	1465	activates	activate	VBZ
1466	1468	de	de	FW
1469	1473	novo	novo	FW
1474	1483	synthesis	synthesis	NN
1484	1486	of	of	IN
1487	1489	an	an	DT
1490	1500	inhibitory	inhibitory	JJ
1501	1507	factor	factor	NN
1507	1508	,	,	,
1509	1517	possibly	possibly	RB
1518	1521	one	one	CD
1522	1524	or	or	CC
1525	1529	more	more	JJR
1530	1537	members	member	NNS
1538	1540	of	of	IN
1541	1544	the	the	DT
1545	1550	SOCS/	SOCS/	NNP
1551	1558	SSI/CIS	SSI/CIS	NNP
1559	1563	gene	gene	NN
1564	1570	family	family	NN
1570	1571	,	,	,
1572	1579	capable	capable	JJ
1580	1582	of	of	IN
1583	1594	suppressing	suppress	VBG
1595	1605	activation	activation	NN
1606	1608	of	of	IN
1609	1614	STAT6	stat6	NN
1615	1617	by	by	IN
1618	1622	IL-4	il-4	NN
1623	1626	and	and	CC
1627	1632	IL-13	il-13	NN
1632	1633	.	.	.

1634	1641	Because	because	IN
1642	1647	STAT6	STAT6	NNP
1648	1658	activation	activation	NN
1659	1664	plays	play	VBZ
1665	1667	an	an	DT
1668	1677	essential	essential	JJ
1678	1682	role	role	NN
1683	1685	in	in	IN
1686	1704	IL-4/IL-13-induced	il-4/il-13-induced	JJ
1705	1709	gene	gene	NN
1710	1720	expression	expression	NN
1720	1721	,	,	,
1722	1725	the	the	DT
1726	1733	ability	ability	NN
1734	1736	of	of	IN
1737	1745	IFN-beta	IFN-beta	NNP
1746	1749	and	and	CC
1750	1759	IFN-gamma	IFN-gamma	NNP
1760	1762	to	to	TO
1763	1770	inhibit	inhibit	VB
1771	1776	STAT6	STAT6	NNP
1777	1785	activity	activity	NN
1786	1794	provides	provide	VBZ
1795	1797	an	an	DT
1798	1809	explanation	explanation	NN
1810	1813	for	for	IN
1814	1817	how	how	WRB
1818	1822	IFNs	ifn	NNS
1823	1826	can	can	MD
1827	1835	suppress	suppress	VB
1836	1856	IL-4/IL-13-inducible	il-4/il-13-inducible	JJ
1857	1861	gene	gene	NN
1862	1872	expression	expression	NN
1872	1873	.	.	.